Clinical trials: Hypertrophic Cardiomyopathy (HCM)
Hypertrophic Cardiomyopathy (HCM)
One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance
This is a multi-center, observational study aiming to establish a precision diagnosis scheme and multi-dimensional risk prediction models for Hypertrophic Cardiomyopathy (HCM). The study plans to enroll 10000 adult HCM patients.
- Trial name
- NCT07336290
- Volunteers
- 10,000 people
- Sponsor
- Minjie Lu
Hypertrophic Cardiomyopathy, Myocardial Perfusion Imaging
Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging
Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride…
- Trial name
- NCT03150342
- Testing
- myocardial perfusion imaging
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Far Eastern Memorial Hospital
Hypertrophic Cardiomyopathy, Obstruction
4D-flow MRI to Assess Left Ventricular Obstruction in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a frequent cardiac pathology with an estimated prevalence of 1/500 in France. The main risk factor for sudden death in this pathology is the presence and extent of left ventricular…
- Conditions
- Hypertrophic Cardiomyopathy, Obstruction, Echocardiography
- Trial name
- CMHFLUX (NCT04439942)
- Testing
- cardiac magnetic resonance imaging (MRI)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cardiopulmonary Exercise Test, Hypertrophic Cardiomyopathy
Exercise Oxygen Kinetic and Cardiac Output in Hypertrophic Cardiomyopathy
Fatigue and dyspnea that reduce exercise performance are common symptoms in patients with hypertrophic cardiomyopathy. Since the cause of this functional limitation has not yet been described, this study aims to evaluate the…
- Conditions
- Cardiopulmonary Exercise Test, Hypertrophic Cardiomyopathy, Cardiac Output Measurement
- Trial name
- NCT05754489
- Where
- 3 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Centro Cardiologico Monzino
Non-obstructive Hypertrophic Cardiomyopathy
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
Aim: to compare the treatment effects of Bisoprolol (beta 1 receptor specific beta blocker (BB)) and Verapamil (cardio-specific calcium channel blockers (CCB)) in patients with non-obstructive hypertrophic cardiomyopathy (HCM).
- Trial name
- TEMPO II (NCT05569382)
- Testing
- Verapamil, Bisoprolol
- Where
- 4 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Morten Steen Kvistholm Jensen
Hypertrophic Cardiomyopathy, Heart Failure
Empagliflozin in Hypertrophic Cardiomyopathy
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study.
- Trial name
- EMPA-REPAIR (NCT05182658)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 250 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Hypertrophic Cardiomyopathy
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
Aims and objectives: The primary objective of this study is to assess whether a structured exercise program improves cardiac relaxing properties in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- WEDGE-HCM (NCT03537183)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Bispebjerg Hospital
Coronary Disease, Healthy
Study of Blood Flow in Heart Muscle
Blood flows to areas of the heart providing oxygen and fuel to the pumping muscle. Occasionally the arteries providing the fuel can become blocked. This occurs in coronary artery disease.
- Conditions
- Coronary Disease, Healthy, Hypertrophic Cardiomyopathy, Myocardial Ischemia
- Trial name
- NCT00001631
- Testing
- Magnetic resonance imaging
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obesity, Hypertrophic Cardiomyopathy
Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy
In this study, the investigators evaluated the association between various measures of adiposity [BMI and waist circumference (WC)] and clinical outcomes in Asian patients with hypertrophic cardiomyopathy, using a nationwide…
- Conditions
- Obesity, Hypertrophic Cardiomyopathy, Cardiovascular Morbidity
- Trial name
- Paradox (NCT05645939)
- Testing
- Diasgnosis of hypertrophic cardiomyopathy
- Where
- South Korea
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Ajou University School of Medicine
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM)
Hypertrophic Obstructive Cardiomyopathy (HOCM) is an inherited cardiac condition which causes the heart muscle to become abnormally thick causing obstruction of blood flow in the heart.
- Trial name
- EMORI-HCM (NCT05257772)
- Testing
- AV Delay Optimised RV Pacing
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Cardiac Rehabilitation
"Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy".
Hypertrophic cardiomyopathy (HCM) is the most common hereditary disease characterized by left ventricular hypertrophy and consequently left ventricular diastolic dysfunction.
- Trial name
- NCT03178357
- Testing
- Cardiac rehabilitation + standard therapy, Standard therapy
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Hypertrophic Cardiomyopathy
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death.
- Trial name
- NCT02234336
- Testing
- Noncontrast echocardiography, Contrast Echocardiography, Cardiac magnetic resonance imaging
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Mayo Clinic
Hypertrophic Cardiomyopathy
Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement
Biventricular Pacing has been shown an improvement of symptoms in patients with heart failure. A temporary pacing is necessary in patients after cardiac procedures.
- Trial name
- BIVENT (NCT01081093)
- Testing
- additional temporary pacewire
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
- Trial name
- NCT00001878
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Obstructive Cardiomyopathy
Residual or Recurrent Obstruction After Septal Myectomy
The goal of this observational study is to report the outcomes after septal myectomy in young children and infants and identify the mechanisms of residual or recurrent obstruction after surgery.
- Trial name
- NCT05687487
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Hypertrophic Cardiomyopathy
Exercise Training in Patients With Hypertrophic Cardiomyopathy
Exercise training (ET) is highly beneficial in heart failure patients and has been suggested to confer significant symptomatic and functional improvements in patients with diastolic dysfunction.
- Trial name
- NCT01518114
- Testing
- Exercise Training
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Hypertrophic Obstructive Cardiomyopathy
The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy
Liwen procedure is generally safe and effective in treating hypertrophic cardiomyopathy, but a small proportion of patients have complications after the operation.
- Trial name
- NCT06003478
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Xijing Hospital
Coronary Cicrovascular Dysfunction, Hypertrophic Cardiomyopathy Patients
Prognostic Significance of CMD Assessed by IMR in HCM Patients
The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions.
- Trial name
- caIMR-HCM (NCT06190704)
- Testing
- caIMR
- Volunteers
- 191 people
- Sponsor
- Ya-Wei Xu
Left Ventricular Hypertrophy
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study
- Trial name
- NCT01198899
- Testing
- blood sampling
- Where
- 9 sites in Belgium
- Volunteers
- 540 people
- Sponsor
- University Hospital, Ghent
Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR)
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture.
- Conditions
- Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
- Trial name
- Amylo (NCT01623245)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Thibaud Damy